We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $17 · 7 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Aurinia Pharmaceuticals stock (CA05156H1070): shares steady on Nasdaq after Q1 2026 earnings beat - AD HOC NEWS
Aurinia Pharmaceuticals stock (CA05156H1070): shares steady on Nasdaq after Q1 2026 earnings beat AD HOC NEWS
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison Intellectia AI
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) ChartMill
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
Discipline and Rules-Based Execution in AUPH Response Stock Traders Daily
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $0.25 | — | — | $80.2M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.16 | — | — | $62.47M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.03 | — | — | $175.27M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.07 | — | — | $107.5M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 12. 03. | Leerink Partners | — | Downgrade | Outperform → Market Perform | — | Leerink Partners: Outperform → Market Perform |
| 2025. 11. 07. | Jefferies | — | Upgrade | Hold → Buy | — | Jefferies: Hold → Buy |
| 2025. 11. 05. | RBC Capital | — | Downgrade | Outperform → Sector Perform | — | RBC Capital: Outperform → Sector Perform |
| 2025. 08. 02. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2024. 09. 17. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
| 2024. 09. 10. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 3,428,705 | $50.81B | 0.04% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,962,742 | $31.31B | 0.05% | — | New position |